Mirati receives approval from UK’s MHRA for NSCLC therapy
Krazati has been approved as a monotherapy to treat adult patients with advanced NSCLC with KRASG12C mutation and who have progressive disease after previous therapy with, or intolerance
Eli Lilly and Company has entered a licensing agreement worth up to $1.26bn with Hanmi Pharm to develop, manufacture and commercialise Hanmi’s biologic drug candidate, sonefpeglutide (a LAPS GLP-2 analogue), worldwide excluding Korea.
Under the multi-year, multi-programme collaboration, the companies will discover, develop, and commercialise therapies for cancer patients. Prelude’s capabilities in medicinal chemistry, targeted protein degradation and clinical development will
Under the deal, Moderna will utilise Caris’ library of de-identified, multi-modal data solutions generated from whole exome sequencing, whole transcriptome sequencing, and protein analyses, in addition to claims